Insider Buy ·Filed Oct 21, 2026
Insider cluster: 1 insiders, $144K total
Actionable Insight ▲ Bullish
Monitor for any subsequent filings (e.g., additional insider buys, earnings, or corporate events) that could confirm or contradict the CFO's bullish signal.
Latest settled — T+1d
RAPP ▼ -2.26% at T+1d
LONG call ✗ call lost -2.26% · α vs SPY -1.74% · entry $26.53 → $25.93
T+1d
-2.26%
call -2.26% · α -1.74%
$25.93
settled 4d ago
T+5d
Pending
in 2d
T+20d
Pending
in 23d
T+60d
Pending
in 3mo
Price Chart
Loading chart...
Executive Summary
Rapport Therapeutics CFO Troy Ignelzi purchased $144K worth of RAPP shares on the open market at $26.10 per share on October 21, 2026. This is a standalone conviction buy by a C-suite officer, a recognized bullish signal per insider-trading literature.
Key Financial Metrics
Direction
buying
Total Value
$144.0K
Insiders
1
Key Facts
- CFO Troy Ignelzi purchased 5,500 shares at $26.10 per share for a total of $144,000 on October 21, 2026.
- The purchase is an open-market transaction (code P) with no 10b5-1 plan indication.
- This is a single insider buy, not part of a cluster, but the CFO is a C-suite officer.
- The $144K purchase is a meaningful absolute dollar amount for a standalone buy.
Financial Impact
$144,000 open-market purchase by CFO
insider ownership
Risk Factors
- A single insider buy, while positive, is less informative than a cluster; the CFO's purchase could be personal portfolio rebalancing.
- No market cap data is available to assess proportionality relative to company size.
Investment Themes
Biotech & Drug Discovery
Documents Analyzed
This report is based on 1 SEC document filed with EDGAR.
| Document | Accession Number |
|---|---|
| INSIDER-BUY Data (Synthetic) | 0001193125-26-428018 |
22 reports for RAPP
67% Hit rate @ T+5 Went positive at some point 6 of 7 best @ T+60▲ +24.87%
Filters
Rows
| Type | Now | ||||
|---|---|---|---|---|---|
Oct 23, 2026 2d ago | Insider Cluster | $26.00 | awaiting T+5 | — | $25.93 (−0.27%) |
Oct 22, 2026 4d ago | Insider Cluster | $27.33 | awaiting T+5 | — | $25.93 (−5.12%) |
Oct 21, 2026 4d ago | Insider Buy | $26.53 | awaiting T+5 | — | $25.93 (−2.26%) |
Oct 20, 2026 6d ago | 8-K | $29.37 | awaiting T+5 | — | $25.93 (−11.71%) |
Oct 6, 2026 19d ago | 144 | $30.86 $28.33 | ▲ +8.20% | ▲ +7.22% | $25.93 (+15.98%) |
Oct 1, 2026 24d ago | Insider Cluster | $32.17 $30.65 | ▼ −4.72% | ▼ −5.89% | $25.93 (−19.40%) |
Aug 26, 2026 8w ago | Insider Cluster | $50.83 $47.65 | ▼ −6.26% | ▼ −6.52% | $25.93 (−48.99%) |
Aug 5, 2026 11w ago | 8-K | $42.44 $47.73 | ▲ +12.46% | ▲ +12.11% | $25.93 (−38.90%) |
Jul 1, 2026 16w ago | Insider Cluster | $38.97 $41.75 | ▲ +7.13% | ▲ +5.77% | $25.93 (−33.46%) |
Jun 30, 2026 16w ago | 144 | $39.39 $39.72 | ▲ +0.84% | ▲ +0.58% | $25.93 (−34.17%) |
Showing 10 of 22
US Market Status
Market Closed — Opens in 2h 43m
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers